SCHEMBL6509303

SCHEMBL6509303

COc1ccc(Sc2cc(Nc3cccc(F)c3)nc(NC(=O)[C@H](CC(C)C)NCCN3CCOCC3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.40
ROCK2 O75116 1/20 0.39
PSMB8 P28062 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 2/20 0.37
GSK3A P49840 2/20 0.37
SRC P12931 1/20 0.37
SYK P43405 1/20 0.37
MAPK14 Q16539 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
TACR2 P21452 2/20 0.36
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36
RET P07949 1/20 0.36
AVPR1B P47901 1/20 0.36
PLK4 O00444 1/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509302 0.89 PDPK1 (0.41) PDPK1PSMB8MEN1KMT2APOLB
SCHEMBL6512771 0.87 PDPK1 (0.44) PDPK1PSMB8MEN1KMT2APOLB
SCHEMBL6513421 0.82 PLK4 (0.38) PDPK1PSMB8SYKPLK4CYP2C19
SCHEMBL6512111 0.79 CTSK (0.38) POLBCYP2C19CYP2C9KDM4ESMN1; SMN2
SCHEMBL6512117 0.79 CTSK (0.38) POLBCYP2C19CYP2C9KDM4ESMN1; SMN2
SCHEMBL6512168 0.79 CTSK (0.40) POLBCYP2C19CYP2C9SMN1; SMN2CYP2D6
SCHEMBL6512174 0.79 CTSK (0.40) POLBCYP2C19CYP2C9SMN1; SMN2CYP2D6
SCHEMBL6531499 0.78 PDPK1 (0.45) PDPK1MEN1KMT2APOLBGSK3A
SCHEMBL6506223 0.78 CTSK (0.42) MEN1KMT2APOLBCYP2C19CYP2C9
SCHEMBL6510161 0.77 CTSK (0.44) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO claimed